{"id":5874,"date":"2024-09-19T16:57:00","date_gmt":"2024-09-19T16:57:00","guid":{"rendered":"https:\/\/www.enyopharma.com\/fr\/?p=5874"},"modified":"2025-01-17T17:02:10","modified_gmt":"2025-01-17T17:02:10","slug":"5874","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/5874\/","title":{"rendered":"R\u00e9union de la FEDERG, Federation of European Patient Groups affected by Rare\/Genetic Kidney Diseases"},"content":{"rendered":"<p>14 Septembre 2024<br \/>\nMartorell, Espagne<\/p>\n<p>La F\u00e9d\u00e9ration europ\u00e9enne des groupes de patients touch\u00e9s par des maladies r\u00e9nales rares\/g\u00e9n\u00e9tiques, FEDERG (Federation of European Patient Groups affected by Rare\/Genetic Kidney Diseases), organisait sa r\u00e9union \u00ab Combattre pour notre f\u00e9d\u00e9ration FEDERG f2f Members \u00bb le 14 septembre \u00e0 Martorell en Espagne. L&#8217;objectif de la r\u00e9union \u00e9tait de planifier de nouvelles actions pratiques qui contribuent \u00e0 am\u00e9liorer et promouvoir la connaissance de ces pathologies, \u00e0 promouvoir la recherche et \u00e0 participer activement au processus de d\u00e9cision politique pour l&#8217;inclusion de nos pathologies.<br \/>\nENYO Pharma \u00e9tait pr\u00e9sent pour pr\u00e9senter son \u00e9tude clinique de Phase 2 ALPESTRIA-1 pour le syndrome d&#8217;Alport.<\/p>\n<p><a href=\"https:\/\/federg.org\/fighting-for-our-federation-federg-f2f-members-meeting-september-14-martorell\" target=\"_blank\" rel=\"noopener\">https:\/\/federg.org\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>14 Septembre 2024<br \/>\nMartorell, Espagne<\/p>\n<p>La F\u00e9d\u00e9ration europ\u00e9enne des groupes de patients touch\u00e9s par des maladies r\u00e9nales rares\/g\u00e9n\u00e9tiques, FEDERG (Federation of European Patient Groups affected by Rare\/Genetic Kidney Diseases), organisait sa r\u00e9union \u00ab Combattre pour notre f\u00e9d\u00e9ration FEDERG f2f Members \u00bb le 14 septembre \u00e0 Martorell en Espagne. L&#8217;objectif de la r\u00e9union \u00e9tait de planifier de nouvelles actions pratiques qui contribuent \u00e0 am\u00e9liorer et promouvoir la connaissance de ces pathologies, \u00e0 promouvoir la recherche et \u00e0 participer activement au processus de d\u00e9cision politique pour l&#8217;inclusion de nos pathologies.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/5874\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5874","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/events-fr\/\" rel=\"category tag\">\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"14 Septembre 2024 Martorell, Espagne La F\u00e9d\u00e9ration europ\u00e9enne des groupes de patients touch\u00e9s par des maladies r\u00e9nales rares\/g\u00e9n\u00e9tiques, FEDERG (Federation of European Patient Groups affected by Rare\/Genetic Kidney Diseases), organisait sa r\u00e9union \u00ab Combattre pour notre f\u00e9d\u00e9ration FEDERG f2f Members \u00bb le 14 septembre \u00e0 Martorell en Espagne. L&#8217;objectif de la r\u00e9union \u00e9tait de planifier&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5874"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5874\/revisions"}],"predecessor-version":[{"id":5878,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5874\/revisions\/5878"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}